Donepezil delays progression to AD in MCI subjects with depressive symptoms

Neurology

Volumn 72, Issue 24, 2009, Pages 2115-2121

  Lu, P H ^a,e   Edland, S D ^b   Teng, E ^a,c   Tingus, K ^a   Petersen, R C ^d   Cummings, J L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d Mayo Clinic   (United States)

^e Mary S Easton Center for Alzheimer's Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL; SYMPTOM;

EID: 67649488056     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181aa52d3     Document Type: Article

References (40)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
2. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:383-389.
3. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
4. DeCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004;63:220-227.
5. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006;63:916-924.
6. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-1403.
7. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006;63:693-699.
8. Encinas M, De Juan R, Marcos A, et al. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease. Eur J Nucl Med Mol Imaging 2003;30:1473-1480.
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
10. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-1483.
11. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004;18:17-21.
12. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:253-259.
13. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004;61:1290-1293.
14. Gabryelewicz T, Styczynska M, Luczywek E, et al. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry 2007;22:563-567.
15. Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clin Neurol Neurosurg 2006;108:733-736.
16. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry 1999;56:261-266.
17. Rozzini L, Chilovi BV, Trabucchi M, Padovani A. Depression is unrelated to conversion to dementia in patients with mild cognitive impairment. Arch Neurol. 2005;62: 505; author reply 505-506.
18. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219.
19. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-538.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Wechsler D. Wechsler Memory Scale, Revised: Administration and Scoring Manual. San Antonio: The Psychological Corporation; 1981.
22. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637-639.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
25. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
26. Zubenko GS, Moossy J. Major depression in primary dementia. Clinical and neuropathologic correlates Arch Neurol 1988;45:1182-1186.
27. Forstl H, Levy R, Burns A, Luthert P, Cairns N. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease-a hypothesis. Pharmacopsychiatry 1994;27:11-15.
28. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988;24:233-242.
29. Craig AH, Cummings JL, Fairbanks L, et al. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
30. Hirono N, Mori E, Ishii K, et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 1998;50:380-383.
31. Apostolova LG, Akopyan GG, Partiali N, et al. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:91-97.
32. Li YS, Meyer JS, Thornby J. Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 2001;16:718-727.
33. Adler G, Chwalek K, Jajcevic A. Six-month course of mild cognitive impairment and affective symptoms in late-life depression. Eur Psychiatry 2004;19:502-505.
34. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363:2105-2115.
35. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
36. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-512.
37. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155.
38. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimer Dis 2003;5:39-48.
39. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883.
40. Enns MW, Larsen DK, Cox BJ. Discrepancies between self and observer ratings of depression: the relationship to demographic, clinical and personality variables. J Affect Disord 2000;60:33-41.